Cofactor Genomics Acquires Narus Biotechnologies
News Feb 04, 2016
This acquisition advances Cofactor’s expansion into RNA-based diagnostics and further solidifies their plans for the development and delivery of RNA-based tests for cancer and neurodegenerative disease. Cofactor’s initial products are aimed at the pre-clinical and clinical segments of the pharmaceutical market, where Cofactor has nine of the world’s largest pharmaceutical companies under contract for studies using RNA to understand disease.
“In addition to acquiring Narus’ assets related to RNA biomarkers, we gain an extremely talented team that is already helping to accelerate Cofactor’s RNA-based diagnostic roadmap,” stated Dr. Jarret Glasscock, Cofactor’s CEO. “This acquisition brings two major changes to Cofactor: it establishes Cofactor’s San Francisco presence and secures the resources necessary to change the face of medicine by using RNA to detect disease and monitor treatment progression.”
“There is a multitude of diseases where a tissue biopsy is just not feasible and current techniques like cell-free DNA are noninformative. We’re excited to integrate the techniques we’ve developed using cell-free RNA with the proven track record of an institution like Cofactor,” stated Raman Talwar, Narus co-founder and Cofactor’s newly appointed Director of Diagnostic Development.
Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast CancerNews
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Fraunhofer and Mologic Partner on Point-of-Care Diagnosis and Antibiotic Susceptibility Test for UTIsNews
Test will allow better targeting of prescription antibiotics and address growing antimicrobial resistance.READ MORE